Conference Proceedings

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Maria Mateos, Sundar Jagannath, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Irina Kryachok, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim A Doronin, Ganna Usenko, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P Venner, Mamta Garg, Don A Stevens Show all

Blood | American Society of Hematology | Published : 2020

Abstract

Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and activation of tumor suppressor proteins, leading to cancer cell apoptosis. Selinexor has demonstrated antimyeloma activity in triple class refractory multiple myeloma (MM) [Chari et al. NEJM 2019]. Selinexor synergizes with proteasome inhibitors (PIs) in PI-sensitive and -resistant cell lines and produces high response rates in patients with PI refractory and non-refractory MM. (Bahlis et al. Blood 2018). In the phase 3 BOSTON study, the combination of once weekly (QW) selinexor, QW bortezomib and dexamethasone (SVd) in pati..

View full abstract

University of Melbourne Researchers

Citation metrics